Ravano, Veronica http://orcid.org/0000-0002-1532-9664
Piredda, Gian Franco http://orcid.org/0000-0002-8449-6634
Krasensky, Jan http://orcid.org/0000-0002-5605-8821
Andelova, Michaela http://orcid.org/0000-0002-3812-7483
Uher, Tomas http://orcid.org/0000-0003-3160-9022
Srpova, Barbora http://orcid.org/0000-0002-8092-6625
Havrdova, Eva Kubala http://orcid.org/0000-0002-9543-4359
Vodehnalova, Karolina http://orcid.org/0000-0002-0675-2866
Horakova, Dana http://orcid.org/0000-0003-1915-0036
Nytrova, Petra http://orcid.org/0000-0003-4885-602X
Disselhorst, Jonathan A. http://orcid.org/0000-0002-2924-1866
Hilbert, Tom http://orcid.org/0000-0001-8207-4908
Maréchal, Bénédicte http://orcid.org/0000-0001-7866-2854
Thiran, Jean-Philippe http://orcid.org/0000-0003-2938-9657
Kober, Tobias http://orcid.org/0000-0001-7598-9456
Richiardi, Jonas http://orcid.org/0000-0002-6975-5634
Vaneckova, Manuela http://orcid.org/0000-0002-8784-7997
Funding for this research was provided by:
Roche (NTC03706118)
Czech Ministry of Health (NU 22-04-00193)
Czech Ministry of Education (Project Cooperation LF1 - reasearch area Neuroscience)
Charles University and General University Hospital in Prague (RVO VFN 64165)
EPFL Lausanne
Article History
Received: 7 July 2023
Revised: 21 September 2023
Accepted: 24 September 2023
First Online: 11 October 2023
Declarations
:
: The authors of this manuscript declare relationships with the following companies: V. Ravano, J-P. Thiran and J. Richiardi have no financial or proprietary interests in any material discussed in this article. G.F. Piredda, J.A. Disselhorst, T. Hilbert, B. Maréchal and T. Kober are employed by Siemens Healthineers International AG, Switzerland. M. Vaneckova received compensation for speaker honoraria, travel and consultant fees from Biogen, Sanofi Genzyme, Novartis, Roche and Teva, as well as support for research activities from Biogen. J. Krasensky received financial support for research activities from Biogen Idec. M. Andelova received financial support for conference travel from Novartis, Genzyme, Merck Serono, Biogen Idec and Roche. T. Uher received financial support for conference travel from Biogen Idec, Novartis, Sanofi, Roche and Merck Serono and speaker honoraria from Biogen Idec, Novartis and Roche as well as support for research activities from Biogen Idec and Sanofi. B. Srpova received compensation for traveling and conference fees from Novartis, Sanofi Genzyme, Biogen Idec, Roche and Merck as well as support for research activities from Biogen Idec. E.K. Havrdova received speaker honoraria and consultant fees from Biogen Idec, Merck Serono, Novartis, Genzyme and Teva, as well as support for research activities from Biogen Idec and Merck Serono. K. Vodehnalova received compensation for traveling, conference fees and consulting fees from Merck, Teva, Sanofi Genzyme, Biogen Idec, Novartis, Roche. D. Horakova received compensation for travel, speaker honoraria, and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche and Teva, as well as support for research activities from Biogen Idec. She was also supported by the Czech Ministry of Education project Progress Q27/LF1. P. Nytrova received speaker honoraria and consultant fees from Biogen, Novartis, Merck, Roche, and financial support for research activities from Roche and Merck.
: The study was conducted according to the Declaration of Helsinki and The Ethics Committee of the General Teaching Hospital in Prague provided approval for the examination of both MS patients and for healthy individuals. All participants gave their written informed consent.
: Written informed consent was obtained from all patients in this study.
: Not applicable as no individual details are reported.